Fig. 5: Pyroptosis is activated by p-MAP4 and NLRP3 suppression alleviated p-MAP4-induced angiogenesis inhibition in vitro. | Cell Death Discovery

Fig. 5: Pyroptosis is activated by p-MAP4 and NLRP3 suppression alleviated p-MAP4-induced angiogenesis inhibition in vitro.

From: Microtubule associated protein 4 (MAP4) phosphorylation reduces cardiac microvascular density through NLRP3-related pyroptosis

Fig. 5

A Representative immunoblotting bands of GSDMD-N, GSDMD, pro-IL-1β, mature IL-1β, and IL-18 in HUVECs; n = 5. B–F The statistical analysis of GSDMD-N, GSDMD, pro-IL-1β, mature IL-1β, and IL-18. *p < 0.05 and **p < 0.01 versus the CMV-null group. ##p < 0.01 and ###p < 0.001 versus the Ad-MAP4 (Ala) group. N.S. represents no statistical difference; n = 5. G A scatter diagram showing the concentration of IL-18 in the medium of HUVECs. **p < 0.01 versus the Con group; n = 8. H Representative confocal images of co-staining with Hoechst 33342 and PI in HUVECs. Scale bar, 10 µm; n = 3. I A scatter diagram showing the statistical analysis of HUVECs with PI signal (%). ***p < 0.001 versus the CMV-null group; n = 3. J A scatter diagram showing cytotoxicity, represented by the release of LDH, in HUVECs. **p < 0.01 versus the Con group; n = 8. K Representative immunoblotting bands of NLRP3 and p-MAP4 after NLRP3 siRNA treatment; n = 5. L The statistical analysis of p-MAP4 in HUVECs treated by NLRP3 siRNAs. N.S. represents no statistical difference; n = 5. M The statistical analysis of NLRP3 in HUVECs treated by NLRP3 siRNAs. N.S. represents no statistical difference; **p < 0.01 versus the NC group; ***p < 0.001 versus the NC group; n = 5. N The representative image of tube formation assay in HUVECs treated with Ad-MAP4 (Glu) with or without NLRP3 siRNA. Scale bar, 10 µm; n = 3. O The statistical analysis of capillary length. **p < 0.01 and ***p < 0.001 versus the CMV-null group. ##p < 0.01 versus the Ad-MAP4 (Glu) + siNLRP3 group. N.S. represents no statistical difference; n = 3.

Back to article page